Probiodrug to Present Phase 2a Trial Results of Its Alzheimer’s Therapy PQ912 in Boston

Probiodrug to Present Phase 2a Trial Results of Its Alzheimer’s Therapy PQ912 in Boston
Probiodrug‘s PQ912 decreased markers of inflammation and damage in the nerve cell connections of Alzheimer’s patients, according to a Phase 2a clinical trial. The company will present the results of the SAPHIR trial, which covered the therapy’s safety and effectiveness, at the 10th Clinical Trials on Alzheimer’s Disease Conference in Boston, Nov. 1-4. Dr. Philip Scheltens, director of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *